Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John W Marks

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Cancer Research|July 23, 2003
Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin geloninMichael G Rosenblum, Lawrence H Cheung, Yuying Liu, et al.
International Journal of Cancer|December 30, 2003
Recombinant single-chain antibody fusion construct targeting human melanoma cells and containing tumor necrosis factorYuying Liu, Lawrence H Cheung, John W Marks, et al.
The Journal of Physical Chemistry. B|July 21, 2006
Stable containment of radionuclides on the nanoscale by cut single-wall carbon nanotubesYuri A Mackeyev, John W Marks, Michael G Rosenblum, et al.
Molecular Cancer Therapeutics|March 18, 2004
Retinoic acid-induced CD38 antigen as a target for immunotoxin-mediated killing of leukemia cellsKapil Mehta, Larry Ocanas, Fabio Malavasi, et al.
Translational Oncology|December 23, 2011
Cell Internalization Studies of Gadofullerene-(ZME-018) Immunoconjugates into A375m Melanoma CellsChristopher Scott Berger, John W Marks, Robert D Bolskar, et al.
Cancer Research|November 26, 2009
Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studiesYu Cao, James D Marks, John W Marks, et al.
Molecular Cancer Therapeutics|March 16, 2013
Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neuYu Cao, Khalid A Mohamedali, John W Marks, et al.
Molecular Cancer Therapeutics|February 3, 2007
The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMAMi-Ae Lyu, Lawrence H Cheung, Walter N Hittelman, et al.
Cancer Research|June 17, 2006
Aptamer:toxin conjugates that specifically target prostate tumor cellsTed C Chu, John W Marks, Laura A Lavery, et al.
Molecular Cancer Therapeutics|May 19, 2011
Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cellsHong Zhou, John W Marks, Walter N Hittelman, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Cancer Research|July 23, 2003
Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin geloninMichael G Rosenblum, Lawrence H Cheung, Yuying Liu, et al.
International Journal of Cancer|December 30, 2003
Recombinant single-chain antibody fusion construct targeting human melanoma cells and containing tumor necrosis factorYuying Liu, Lawrence H Cheung, John W Marks, et al.
The Journal of Physical Chemistry. B|July 21, 2006
Stable containment of radionuclides on the nanoscale by cut single-wall carbon nanotubesYuri A Mackeyev, John W Marks, Michael G Rosenblum, et al.
Molecular Cancer Therapeutics|March 18, 2004
Retinoic acid-induced CD38 antigen as a target for immunotoxin-mediated killing of leukemia cellsKapil Mehta, Larry Ocanas, Fabio Malavasi, et al.
Translational Oncology|December 23, 2011
Cell Internalization Studies of Gadofullerene-(ZME-018) Immunoconjugates into A375m Melanoma CellsChristopher Scott Berger, John W Marks, Robert D Bolskar, et al.
Cancer Research|November 26, 2009
Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studiesYu Cao, James D Marks, John W Marks, et al.
Molecular Cancer Therapeutics|March 16, 2013
Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neuYu Cao, Khalid A Mohamedali, John W Marks, et al.
Molecular Cancer Therapeutics|February 3, 2007
The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMAMi-Ae Lyu, Lawrence H Cheung, Walter N Hittelman, et al.
Cancer Research|June 17, 2006
Aptamer:toxin conjugates that specifically target prostate tumor cellsTed C Chu, John W Marks, Laura A Lavery, et al.
Molecular Cancer Therapeutics|May 19, 2011
Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cellsHong Zhou, John W Marks, Walter N Hittelman, et al.
Pageof 2